Skip to main content

Table 5 Study 478: Potential reasons for not being suitable for repeat first line treatment

From: Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer

Reasons

Relevance to study 478 population

Short time to progression

54% of patients in the trial had a treatment free interval (TFI) of ≤90 days

Residual toxicity to first line regimen

13% of patients in the best supportive care + topotecan arm and 10% in the best supportive care arm had residual toxicity

Patient preference not to receive further intravenous chemotherapy

O'Brien et al report that some patients in the study with sensitive SCLC refuse further intravenous chemotherapy because of the risk of toxicity or become unsuitable for standard chemotherapy because of co-morbidities